Month: August 2022

HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) — Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced financial and operating results for the second quarter 2022. Key HighlightsFirst five wells of 2022 capital program put online during quarter and continued one-rig program with spudding of next three well pad Disciplined capital program mitigating inflation and supply chain disruption Outstanding performance in drilling and completion operations – fewer drilling days and higher pump efficiency than plan Construction underway on recently announced strategic acid gas treating facility Anticipate meaningful production and EBITDA growth in second half of 2022Management Comments Richard Little, the Company’s CEO, commented, “The second quarter was all about building momentum as we pivoted towards...

Net Income of $31.8 Million Increases Year-over-Year by 24.4% or $6.2 Million; Adjusted EBITDA Beats Consensus, Reaches All-Time Second Quarter High With 4.4% Increase in Q2 2022 Compared to Q2 2021 RICHMOND, Va., Aug. 08, 2022 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO) (“ARKO” or the “Company”), one of the largest convenience store operators and fuel wholesalers in the United States, today announced financial results for the quarter ended June 30, 2022. Second Quarter 2022 Key HighlightsOperating income was $48.3 million for the quarter, an increase of 5.5% compared to $45.8 million in Q2 2021 Net income was $31.8 million, an increase of $6.2 million or 24.4% compared to $25.6 million in Q2 2021 Adjusted EBITDA increased 4.4% to $79.0 million for the quarter compared to $75.7 million in Q2 2021 Merchandise revenue of $431.8...

Gross Premiums Earned Grew 30%Implemented Rate Increases to Offset Inflation TAMPA, Fla., Aug. 08, 2022 (GLOBE NEWSWIRE) — HCI Group, Inc. (NYSE:HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, reported a net loss of $8.5 million, or $1.04 per share, in the second quarter of 2022 compared with net income of $3.8 million, or $0.24 diluted earnings per share, in the second quarter of 2021. Adjusted net loss (a non-GAAP measure which excludes net unrealized gains or losses on equity securities) was $5.4 million, or $0.71 per share, in the second quarter of 2022 compared with adjusted net income of $2.7 million, or $0.11 diluted earnings per share, in the second quarter of 2021. This press release includes an explanation of adjusted net income as well as...

Q2 2022 GAAP diluted EPS of $(0.07) and operating income of $3 million Q2 2022 Adjusted diluted EPS of $(0.03)(1) and adjusted operating income of $4 million(1) MINNEAPOLIS, Aug. 08, 2022 (GLOBE NEWSWIRE) — Sun Country Airlines Holdings, Inc. (“Sun Country Airlines”, “Sun Country”, the “Company”) (NASDAQ: SNCY) today reported financial results for its second quarter ended June 30, 2022. “Despite the second quarter being a historically seasonally weaker quarter, scheduled service TRASM in the quarter was up 29% versus the second quarter 2019 and 13% sequentially versus first quarter 2022. We generated a positive operating profit of $3.4 million and an adjusted operating profit of $4 million despite fuel prices averaging $4.39 per gallon during the quarter,” said Jude Bricker, Chief Executive Officer of Sun Country. “During...

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments. Key developments from Q2 2022 and to date include:Completed dosing in both Part B and Part C (of four parts) of Phase 1/2a Clinical Trial of AT-H201 in healthy volunteers, which the Company was developing as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.Announced plans to shift the development of AT-H201 to more closely align with...

– Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfront payment of $90 million and $422.5 million in potential milestones per product candidate – – A $10 million milestone payment from Merck was triggered upon first patient dosed in a Phase 1 study under the existing cytokine derivative collaboration – – Discussions with FDA held mid-year 2022 signaled that the accelerated approval pathway could be available for STRO-002 in a platinum-resistant ovarian cancer patient population – – Cash, cash equivalents and marketable securities totaled $191.6 million as of June 30, 2022, which, together with the $90 million upfront payment received from Astellas in July 2022, provides a projected cash runway into the first half of 2024, based on current...

BILLERICA, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2022. Second Quarter 2022 SummaryTotal revenue of $15.3 million. Total revenue in the second quarter of 2021 included significant non-recurring royalty revenue. Product revenue of $15.1 million, remained flat year-over-year on a reported basis and increased 1% on a constant currency basis. Conformis hip system revenue of $0.7 million, a decrease of 18% year-over-year. Cash and cash equivalents of $72.6 million as of June 30, 2022.Executive Commentary – Mark Augusti, President and CEO “Our second quarter results show signs that we are on the right long-term path. We were in-line...

FITCHBURG, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) — Micron Solutions, Inc. (OTCQB: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining and injection molding, announced financial results for its second quarter ended June 30, 2022. For the second quarter of 2022, the Company reported $6,536,326 in net sales, as compared to $5,389,735 in the second quarter of 2021, a 21.3% increase. This increase is due to stronger results in our core medical market. Net loss for the second quarter of 2022 was ($210,797) compared to net income of $3,012,992 in the second quarter of 2021 which included a $3,414,000 gain from the sale/leaseback transaction that took place in the second quarter...